Bob, Other than the ones I mention all the time, (GZTC, Genzl, Lgnd, SHMN, etc.) I think that Myriad Genetics (MYGN) has come back to a buying range. And on a "hey, a stock that is actually big enough to buy" basis, Chiron is attractive as all get out. The science there is top-notch. The business plan doesn't exist. <G> But, IMHO, businessmen are easier to find than creative scientists. Just a caveat on that. I thought the same thing, good science, bad business, about Varian in the 1960s. And by the early 1990s, they finally did get their business plan together. So hope this isn't a 2018 starting date for Chiron to get its act in gear. <G>
MB |
